{"id":845660,"date":"2025-05-01T16:50:16","date_gmt":"2025-05-01T20:50:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/"},"modified":"2025-05-01T16:50:16","modified_gmt":"2025-05-01T20:50:16","slug":"cytosorbents-provides-regulatory-update-for-drugsorb-atr","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/","title":{"rendered":"CytoSorbents Provides Regulatory Update for DrugSorb-ATR"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n PRINCETON,\u00a0N.J.<\/span>, May 1, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0CytoSorbents Corporation<\/a><\/u> (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb\u2122-ATR, its FDA-designated Breakthrough Device.\u00a0 DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta\u00ae (ticagrelor, AstraZeneca), a commonly used blood thinner.<\/p>\n

\n

\n
\n \"CytoSorbents
\n <\/a>\n <\/p>\n<\/p><\/div>\n

On April 25, 2025<\/span>, the U.S. Food and Drug Administration (FDA) issued a denial letter regarding the Company’s De Novo Request for DrugSorb-ATR, identifying remaining deficiencies that must be addressed before the De Novo Request can be granted, and the device can be authorized for commercialization in the U.S. \u00a0\u00a0CytoSorbents has since met with the FDA and will continue to have interactive conversations with the agency to try to resolve the remaining issues.\u00a0 However, if these conversations do not lead to a resolution, a formal appeal will be filed within 60 days.\u00a0<\/p>\n

“We remain deeply committed to bringing DrugSorb-ATR to market as an important solution to address the serious, unmet medical need of preventing life-threatening bleeding in CABG patients treated with Brilinta\u00ae,” said Dr. Phillip Chan<\/span>, Chief Executive Officer of CytoSorbents.\u00a0 “With no therapies currently available in the U.S., tens of thousands of patients remain at risk every year.\u00a0 We will continue working closely with FDA and believe we can resolve the remaining issues in a timely manner and still anticipate a final regulatory decision in 2025.”\u00a0<\/p>\n

\n About CytoSorbents Corporation (NASDAQ: CTSO)<\/b>\n <\/p>\n

\n CytoSorbents Corporation<\/a> is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.<\/p>\n

CytoSorbents’ lead product,\u00a0CytoSorb<\/a>\u00ae<\/a><\/sup>, is approved in the\u00a0European Union\u00a0and distributed in over 70 countries worldwide, with more than 270,000 devices used cumulatively to date.\u00a0 CytoSorb was originally launched in the\u00a0European Union\u00a0under CE mark as the first cytokine adsorber.\u00a0 Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for\u00a0ticagrelor<\/a>\u00a0and\u00a0rivaroxaban<\/a>\u00a0removal in cardiothoracic surgery procedures. CytoSorb has also received\u00a0FDA Emergency Use Authorization<\/a>\u00a0in\u00a0the United States\u00a0for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.\u00a0 CytoSorb is not yet approved or cleared in the United States<\/span>.<\/p>\n

In the U.S. and Canada<\/span>, CytoSorbents is developing the DrugSorb\u2122-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs.\u00a0 It has received two\u00a0FDA Breakthrough Device Designations<\/a>:\u00a0 one for the removal of\u00a0ticagrelor<\/a>\u00a0and another for the removal of the\u00a0direct oral anticoagulants (DOAC) apixaban and rivaroxaban<\/a>\u00a0in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures.\u00a0 In September 2024<\/span>, the Company submitted a De Novo Request to the U.S. FDA<\/a> requesting marketing authorization for the DrugSorb-ATR medical device to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024<\/span><\/a>.\u00a0 In November 2024<\/span>, the Company received its MDSAP certification and submitted its Medical Device License (MDL) application to Health Canada<\/a>.\u00a0 DrugSorb-ATR has not been authorized for commercialization in the U.S. or Canada.\u00a0<\/p>\n

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued\u00a0U.S.\u00a0and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY\u00ae, CytoSorb-XL\u2122, HemoDefend-RBC\u2122, HemoDefend-BGA\u2122, VetResQ\u00ae, K+ontrol\u2122, DrugSorb\u2122, ContrastSorb, and others. For more information, please visit the Company’s website at\u00a0https:\/\/ir.cytosorbents.com\/<\/a>\u00a0\u00a0or follow us on\u00a0Facebook<\/a>\u00a0and\u00a0X<\/a>.\u00a0<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany<\/span>, our ability to resolve remaining deficiencies in the FDA denial letter and\/or successfully appeal the FDA’s decision, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025<\/span>, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.<\/p>\n

\n Please Click to Follow Us on Facebook<\/a> and X<\/a><\/u>\n <\/p>\n

\n U.S. Company Contact:
<\/b>
\n Peter J. Mariani<\/span>, Chief Financial Officer
305 College Road East
Princeton, NJ<\/span> 08540
pmariani@cytosorbents.com<\/a>\u00a0<\/p>\n

\n Investor Relations Contact:
<\/b>
\n Aman Patel<\/span>, CFA & Adanna G. Alexander<\/span>, PhD
ICR Healthcare\u00a0
ir@cytosorbents.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/cytosorbents-provides-regulatory-update-for-drugsorb-atr-302444507.html<\/a><\/p>\n

SOURCE Cytosorbents Corp<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire PRINCETON,\u00a0N.J., May 1, 2025 \/PRNewswire\/ —\u00a0CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb\u2122-ATR, its FDA-designated Breakthrough Device.\u00a0 DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta\u00ae (ticagrelor, AstraZeneca), a commonly used blood thinner. On April 25, 2025, the U.S. Food and Drug Administration (FDA) issued a denial letter regarding the Company’s De Novo Request for DrugSorb-ATR, identifying remaining deficiencies that must be addressed before the De Novo Request can be granted, and the device can be authorized for commercialization in … <\/p>\n

Continue reading “CytoSorbents Provides Regulatory Update for DrugSorb-ATR”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-845660","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCytoSorbents Provides Regulatory Update for DrugSorb-ATR - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoSorbents Provides Regulatory Update for DrugSorb-ATR - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PRINCETON,\u00a0N.J., May 1, 2025 \/PRNewswire\/ —\u00a0CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb\u2122-ATR, its FDA-designated Breakthrough Device.\u00a0 DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta\u00ae (ticagrelor, AstraZeneca), a commonly used blood thinner. On April 25, 2025, the U.S. Food and Drug Administration (FDA) issued a denial letter regarding the Company’s De Novo Request for DrugSorb-ATR, identifying remaining deficiencies that must be addressed before the De Novo Request can be granted, and the device can be authorized for commercialization in … Continue reading "CytoSorbents Provides Regulatory Update for DrugSorb-ATR"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-01T20:50:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoSorbents Provides Regulatory Update for DrugSorb-ATR\",\"datePublished\":\"2025-05-01T20:50:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/\"},\"wordCount\":1163,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/\",\"name\":\"CytoSorbents Provides Regulatory Update for DrugSorb-ATR - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"datePublished\":\"2025-05-01T20:50:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoSorbents Provides Regulatory Update for DrugSorb-ATR\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoSorbents Provides Regulatory Update for DrugSorb-ATR - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/","og_locale":"en_US","og_type":"article","og_title":"CytoSorbents Provides Regulatory Update for DrugSorb-ATR - Market Newsdesk","og_description":"PR Newswire PRINCETON,\u00a0N.J., May 1, 2025 \/PRNewswire\/ —\u00a0CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb\u2122-ATR, its FDA-designated Breakthrough Device.\u00a0 DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta\u00ae (ticagrelor, AstraZeneca), a commonly used blood thinner. On April 25, 2025, the U.S. Food and Drug Administration (FDA) issued a denial letter regarding the Company’s De Novo Request for DrugSorb-ATR, identifying remaining deficiencies that must be addressed before the De Novo Request can be granted, and the device can be authorized for commercialization in … Continue reading \"CytoSorbents Provides Regulatory Update for DrugSorb-ATR\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-01T20:50:16+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoSorbents Provides Regulatory Update for DrugSorb-ATR","datePublished":"2025-05-01T20:50:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/"},"wordCount":1163,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/","name":"CytoSorbents Provides Regulatory Update for DrugSorb-ATR - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","datePublished":"2025-05-01T20:50:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-provides-regulatory-update-for-drugsorb-atr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoSorbents Provides Regulatory Update for DrugSorb-ATR"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=845660"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845660\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=845660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=845660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=845660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}